Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03995576
Other study ID # 2019-05-028-004
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 23, 2019
Est. completion date August 12, 2019

Study information

Verified date September 2019
Source Keimyung University Dongsan Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study wants to identify the incidence of inadvertend intercostal or epidural spread of thoracic sympathetic block


Description:

Clinically, sympathetic blocks (SB) have been used widely to relieve the symptoms of SMP or to differentiate between SMP and sympathetically independent pain. In order to an SB has a diagnostic value, it requires the successful disturbance of the sympathetic activity for a proper duration of time.

For the diagnosis of SMP using an SB, it is essential achieving complete interruption of the sympathetic activity while preserving the sensory and motor function. The sympathetic trunk at lumbar region runs on the anterolateral surface of the vertebral column from L1 to L4 levels, and deep to the medial aspect of the psoas major muscle. Therefore, the investigators can hardly find epidural contrast spread during lumbar SB due to an anterior location of lumbar sympathetic ganglion to the lateral vertebral body. However, frequent psoas muscle injection can be encountered due to a close proximity of lumbar sympathetic ganglion.

In contrast to lumbar sympathetic ganglion, the thoracic sympathetic ganglion is not separated from somatic nerves by muscles and connective tissue. Moreover, the upper thoracic ganglion runs on the posterior surface of vertebral column with close proximity to adjacent epidural region.

This difference of thoracic sympathetic ganglion leads to a frequent epidural and intercostal spread if the investigators perform thoracic SB. Such spread to epidural and intercostal space lowers the diagnostic value of thoracic SB. In addition, serious adverse outcome can be encountered if neurolytic agent is injected into epidural or intercostal space for the purpose of thoracic sympathectomy. Considering the diagnostic value and safety of thoracic SB, evaluation of actual incidence of occurrence of intercostal and epidural spread is important.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date August 12, 2019
Est. primary completion date August 12, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- complex regional pain syndrome

- lymphedema after breast cancer surgery

Exclusion Criteria:

- coagulopathy

- infection

- previous spine fusion at thoracic level

Study Design


Related Conditions & MeSH terms


Intervention

Other:
thoracic sympathetic ganglion block
thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body

Locations

Country Name City State
Korea, Republic of Hong ji HEE Daegu
Korea, Republic of Ji Hee Hong Daegu

Sponsors (1)

Lead Sponsor Collaborator
Keimyung University Dongsan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of intercostal spread intercostal spread which appears at fluorosopic view after contrast medium injection 60 seconds after the completion of thoracic sympathetic ganglion block. 60 seconds means the time when the outcome was measured after thoracic sympathetic ganglion block
Primary incidence of epidural spread epidural spread which appears at fluorosopic view after contrast medium injection 60 seconds after the completion of thoracic sympathetic ganglion block. 60 seconds means the time when the outcome was measured after thoracic sympathetic ganglion block
Secondary degree of finger tip skin temperature increase Skin temperature measurement which is observed after successful sympathetic block 5, 10, 15, 20 minutes after the completion of the intervention 5, 10, 15, 20 minutes mean the time that the outcome was measured after performing the intervention